These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 33704654)

  • 1. Orelabrutinib: First Approval.
    Dhillon S
    Drugs; 2021 Mar; 81(4):503-507. PubMed ID: 33704654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tirabrutinib: First Approval.
    Dhillon S
    Drugs; 2020 Jun; 80(8):835-840. PubMed ID: 32382949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China.
    Gu D; Li J; Miao Y
    Expert Opin Pharmacother; 2022 Dec; 23(18):1979-1986. PubMed ID: 36329558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
    Feng Y; Duan W; Cu X; Liang C; Xin M
    Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
    Lucas F; Woyach JA
    Target Oncol; 2019 Apr; 14(2):125-138. PubMed ID: 30927175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zanubrutinib: First Approval.
    Syed YY
    Drugs; 2020 Jan; 80(1):91-97. PubMed ID: 31933167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acalabrutinib: First Global Approval.
    Markham A; Dhillon S
    Drugs; 2018 Jan; 78(1):139-145. PubMed ID: 29209955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
    Lai MZ; Song PR; Dou D; Diao YY; Tong LJ; Zhang T; Xie H; Li HL; Ding J
    Acta Pharmacol Sin; 2020 Mar; 41(3):415-422. PubMed ID: 31316181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological activity of imidazole group-substituted arylaminopyrimidines (IAAPs) as potent BTK inhibitors against B-cell lymphoma and AML.
    Li S; Wu B; Zheng X; Wang C; Zhao J; Sun H; Sun X; Tang Z; Yuan H; Chen L; Ma X
    Bioorg Chem; 2021 Jan; 106():104385. PubMed ID: 33272709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton Tyrosine Kinase Inhibitors: Present and Future.
    Burger JA
    Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel BTK PROTACs for B-Cell lymphomas.
    Zhao Y; Shu Y; Lin J; Chen Z; Xie Q; Bao Y; Lu L; Sun N; Wang Y
    Eur J Med Chem; 2021 Dec; 225():113820. PubMed ID: 34509879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant Btk
    Gui F; Jiang J; He Z; Li L; Li Y; Deng Z; Lu Y; Wu X; Chen G; Su J; Song S; Zhang YM; Yun CH; Huang X; Weisberg E; Zhang J; Deng X
    Br J Pharmacol; 2019 Dec; 176(23):4491-4509. PubMed ID: 31364164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
    Rhodes JM; Mato AR
    Drug Des Devel Ther; 2021; 15():919-926. PubMed ID: 33688166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of AS-1763: A Potent, Selective, Noncovalent, and Orally Available Inhibitor of Bruton's Tyrosine Kinase.
    Kawahata W; Asami T; Kiyoi T; Irie T; Kashimoto S; Furuichi H; Sawa M
    J Med Chem; 2021 Oct; 64(19):14129-14141. PubMed ID: 34529443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies.
    Robak P; Witkowska M; Wolska-Washer A; Robak T
    Expert Opin Drug Discov; 2023; 18(10):1065-1076. PubMed ID: 37438969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
    Liu J; Chen C; Wang D; Zhang J; Zhang T
    Eur J Med Chem; 2021 May; 217():113329. PubMed ID: 33740548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pirtobrutinib: First Approval.
    Keam SJ
    Drugs; 2023 Apr; 83(6):547-553. PubMed ID: 37004673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
    Zhang Z; Zhang D; Liu Y; Yang D; Ran F; Wang ML; Zhao G
    Arch Pharm (Weinheim); 2018 Jul; 351(7):e1700369. PubMed ID: 29741794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.